01—Abstract
Summary
Summary of the 8-K filed June 10, 2025. Cited figures are marked; the original filing is the authoritative source.
On June 10, 2025, Brown & Brown (BRO) agreed to acquire RSC Topco, Inc., the holding company for Accession Risk Management Group (Risk Strategies and One80 Intermediaries), for a gross purchase price of $9.825 billiona.
At closing, net merger consideration is expected to be about $9.4 billionb, comprising roughly $8.1 billion in cash and $1.3 billion in BRO common stock priced at $110.57 (the June 6, 2025 close). A $750 million indemnity escrow secures liabilities tied to certain run-off financial guarantee policies and a domicile restructuring at an RSC captive subsidiary. The HSR waiting period has already expired, and closing is targeted for Q3 2025, subject to other customary conditions and regulatory approvals.
Financing is the key investor consideration. Management plans to fund the cash portion with a $4.0 billionc senior unsecured notes offering (about 5.75% weighted average rate in the pro forma), a $4.0 billion common equity follow-on offering, and cash on hand, with a $9.4 billion 364-day bridge facility from Bank of America and JPMorgan as a backstop. Management states it is committed to maintaining an investment-grade rating.
Management cites RSC's 2024 pro forma adjusted revenue of about $1.7 billiond and pro forma adjusted EBITDA of about $600 million, implying roughly 12x net purchase price to EBITDA including targeted synergies. Management also expects the deal to be mid-teens accretive to 2024 adjusted diluted EPS, with $150 million of targeted run-rate synergies by 2028 and $200-250 million of one-time integration costs over three years. Risk factors are material.
RSC's historical GAAP results show a 2024 net loss of $368.5 million and a Q1 2025 net loss of $97.3 million, driven largely by interest expense and fair value changes in acquisition earn-out obligations. Shareholders' equity was negative at March 31, 2025. The pro forma statements also reflect a sizeable increase in leverage and share count (roughly 36 million new shares from the equity offering plus about 7 million shares for the seller consideration).
Investors will need to weigh these dilution and leverage effects against the expected synergies and accretion. The escrow, captive run-off exposure, and the 5-year staggered lock-up on seller shares are additional items to monitor.
02—Key points
Key Highlights
- Gross purchase price of $9.825B for RSC Topco (Accession), with approximately $9.4B net at closing: about $8.1B cash and $1.3B in BRO stock valued at $110.57 per share
- Financing plan: $4.0B senior unsecured notes, $4.0B common equity follow-on (with 10% over-allotment), cash on hand, and a $9.4B 364-day bridge facility as backstop
- RSC 2024 pro forma adjusted revenue of about $1.7B and pro forma adjusted EBITDA of about $600M; net purchase price roughly 12x EBITDA including targeted synergies
- Management expects the acquisition to be mid-teens accretive to 2024 adjusted diluted EPS, with $150M of targeted run-rate synergies by end of 2028 and $200-250M of one-time integration costs
- $750M indemnity escrow secures liabilities from RSC's financial guarantee/final judgment policies for segregated captive cells and a domicile restructuring unwind
- RSC reported a 2024 GAAP net loss of $368.5M and a Q1 2025 net loss of $97.3M, with negative shareholders' equity at March 31, 2025
- HSR waiting period has expired; closing expected in Q3 2025 subject to remaining customary conditions and regulatory approvals; seller shares subject to a 5-year staggered lock-up
03—Questions
Frequently Asked Questions
How much will Brown & Brown pay for RSC and how is it being paid?
The gross purchase price is $9.825 billion, with net consideration at closing of about $9.4 billion after adjustments. That is roughly $8.1 billion in cash and $1.3 billion in BRO common stock, with share count based on the $110.57 closing price on June 6, 2025. Brown & Brown plans to fund the cash portion through $4.0 billion of new senior notes, a $4.0 billion common equity offering, and cash on hand.
What is the $750 million escrow and what risks does it cover?
The $750 million Indemnity Escrow Fund secures sellers' indemnification for Special Indemnified Matters. These include liabilities tied to certain financial guarantee and final judgment preservation policies issued by an RSC subsidiary for segregated captive cells, and the unwinding of a domicile restructuring of those policies, plus related litigation, run-off costs, and tax items. Claims are paid first from a dedicated FG Policies capital pool, then from the escrow. Remaining funds are released after the FG Committee determines obligations are resolved.
Is the deal likely to be accretive and what are the synergy expectations?
Management estimates the acquired operations will be mid-teens accretive to Brown & Brown's 2024 adjusted diluted EPS, based on inclusion of targeted run-rate synergies. Targeted synergies are $150 million by end of 2028, against $200-250 million of one-time integration costs over three years and about $50 million of transaction costs in 2025. The pro forma GAAP net income for 2024 is reduced to about $816 million from $993 million, mainly reflecting higher interest and amortization. Actual results may differ materially from these estimates.
How will the deal affect Brown & Brown's leverage and share count?
The financing adds about $4.0 billion of new debt, and pro forma long-term debt rises to roughly $7.7 billion, compared with about $3.7 billion historically. Approximately 36 million shares are expected from the equity offering and about 7 million shares will go to RSC sellers, which increases dilution. Management reaffirmed a commitment to maintaining an investment-grade rating. The filing also warns that increased indebtedness could affect covenant flexibility and credit ratings.
04—Continue